Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium

Modern Pathology

Volumn 15, Issue 4, 2002, Pages 365-371

  Al Kushi, Abdulmohsen ^a   Lim, Peter ^a   Aquino Parsons, Christina ^a   Gilks, C Blake ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Endometrial carcinoma; MIB 1; Mitotic index; p53; Papillary serous carcinoma; Proliferative activity

Indexed keywords

CYCLINE; KI 67 ANTIGEN; PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS INDEX; OUTCOMES RESEARCH; PAPILLARY CARCINOMA; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR;

ADENOCARCINOMA, PAPILLARY; BIOLOGICAL MARKERS; CARCINOMA, ENDOMETRIOID; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MITOTIC INDEX; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036227647     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880531     Document Type: Article

References (44)

1. Endometrial carcinoma
2. Endometrial carcinoma
3. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses
4. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium
5. Theories of endometrial carcinogenesis: A multidisciplinary approach
6. The molecular biology of endometrial tumorigenesis: Does it have a message?
7. Pathology, hormonal aspects, and molecular genetics of the two types of emdometrial cancer
8. Uterine papillary serous carcinoma: Evaluation of long-term survival in surgically staged patients
9. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma
10. Uterine serous carcinoma: A morphologically diverse neoplasm with unifying clinicopathologic features
11. Uterine papillary serous carcinoma: Patterns of metastatic spread
12. Uterine papillary serous carcinoma: A clinicopathologic study of 30 cases
13. p53 overexpression and bcl-2 persistence in endometrial carcinoma: Comparison of papillary serous and endometrioid subtypes
14. Immunohistochemical analysis of p53 in gynecologic tumors
15. The significance of alterations in p53 expression in gynaecological neoplasms
16. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma
17. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis
18. p53 expression, p21 expression and the apoptotic index in endometrioid endometrial adenocarcinoma
19. Low-risk endometrial carcinoma: Assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators
20. p53 overexpression in advanced-stage endometrial adenocarcinoma
21. Early stage uterine papillary serous carcinoma of the endometrium: Effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome
22. Ki-67 staining as a means to simplify analysis of tumor cell proliferation
23. Monoclonal antibody Ki-67: Its use in histopathology
24. The Ki-67 protein: Fascinating forms and an unknown function
25. The Ki-67 protein: From the known and the unknown
26. Simple hyperplasia of the endometrium: An evaluation of proliferative activity by Ki-67 immunostaining
27. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation
28. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression
29. Proliferative and apoptotic status in endometrial adenocarcinoma
30. Immunohistochemical analysis of gynecologic tumors
31. The proliferation-associated Ki-67 protein: Definition in molecular terms
32. Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications
33. Cell proliferation indexes: A biomarker in solid tumors
34. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity
35. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: A population-based endometrial carcinoma study
36. MIB-1 in endometrial carcinoma: Prognostic significance with 5-year follow-up
37. Proliferation index determined by MIB-1 and recurrence in endometrial cancer
38. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction
39. Histopathologic grading of ovarian carcinoma: A review and proposal
40. Grading of ovarian carcinomas
41. Diagnostic and prognostic significance of the mitotic index in endometrial adenocarcinoma
42. Aggressive stage I grade 1 endometrial carcinoma
43. Announcements: FIGO stages - 1988 revision
44. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium